Login
Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc.

etonpharma.com

What Do They Do?

Develops and sells treatments for rare diseases, including medicines for children and patients with metabolic and hormone disorders.

How Do They Make Money?

Customers pay for the company's medicines when product is delivered to wholesalers or when stock is shipped to fulfill patient orders. Licensing income can also come from rights deals and development milestones; sales-based royalties are tied to the licensee's product sales.

revenue
SegmentShareRevenue
License
4.1%
FY2022: 47%
Product Sales and Royalties
Sold outright

96%
FY2022: 53%

Who Are Their Customers?

The company sells its medicines to specialty pharmacy and wholesale distributor customers, which handle order fulfillment, storage and distribution; specialty pharmacies then serve patients. The company also earns income from licensing product rights to other companies.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 94% from one customer

Do Revenues Turn Into Profits?

Not on paper. It lost $4.6M in FY2025, but brought in more cash than it spent: $10.2M of free cash flow.

Operating income, FY2025
−1% of revenue
▲ +68% (Loss) vs FY2024 (−$2.6M, −7%)
Net income, FY2025
−6% of revenue
▼ −20% (Loss) vs FY2024 (−$3.8M, −10%)
Free cash flow, FY2025
13% of revenue
▲ +981% vs FY2024 ($943K, 2%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +158%
vs $22.5M in Q3 FY2025
Net income
▲ Turned profitable
vs −$1.9M in Q3 FY2025
  • Aug 5, 2026 Licensed late-stage candidate ASN-001 for infantile hemangiomas Eton agreed to pay an upfront license fee and plans a bridging study before a possible NDA submission.
  • May 19, 2026 Secured U.S. commercialization rights to IMPAVIDO The supply and distribution agreement covers oral capsules for leishmaniasis; commercialization rights begin September 26, 2026.
  • May 1, 2026 Launched HEMANGEOL oral solution for infantile hemangioma The launch includes patient support services and assistance programs.
  • Apr 16, 2026 Judith Matthews was appointed CFO, succeeding James Gruber Matthews assumed the CFO role on June 1, 2026.

Growing. Revenue grew 3.7x in 4 years, from $21.8M in FY2021 to $80M in FY2025, about 38% a year.

Broader commercial product portfolio The latest report describes eight commercial rare disease products, including several acquired medicines; the older report described three commercial products. The newer report also presents a broader set of late-stage candidates.

Fewer out-licensed products described The older report described royalties or milestone income from several products commercialized by partners. The latest report's product overview centers on the company's own commercial medicines and describes licensing income from rights deals and milestones.

Revenue over time
License Product Sales and Royalties
$100M$50M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support